GlassScriptPhysician profile
Roy Tomas Davee
NPI 1184911273
$26,872.32
in general payments reported to CMS, 2019-2025
26 companies · $612 in 2025
The $612 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,127 · 2020: $230 · 2021: $248 · 2022: $17K · 2023: $6,873 · 2024: $950 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,303 · Food and Beverage: $3,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,302.50 |
| Food and Beverage | $3,132.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $20,970.73 | 2022-2023 | Linx Reflux Management System |
| Boston Scientific Corporation | $1,915.02 | 2019-2025 | Apollo Esg Nxt System, Resolution Clip, Acquire |
| Conmed Corporation | $761.27 | 2019-2025 | Conmed Generators, Conmed Biliary |
| Ethicon US, LLC | $459.49 | 2019-2023 | Linx Reflux Management System |
| Medtronic, INC. | $436.08 | 2022-2025 | Nexpowder, Beacon, Barrx |
| Abbvie INC. | $379.75 | 2021-2025 | |
| Apollo Endosurgery US INC | $295.38 | 2022-2023 | Overstitch Endoscopic Suturing System |
| Endogastric Solutions, INC | $241.25 | 2019-2023 | Esophyx |
| Madrigal Pharmaceuticals | $225.43 | 2024-2025 | Rezdiffra, Resmetirom |
| Covidien LP | $209.88 | 2019-2020 | |
| Olympus America INC. | $183.06 | 2023 | Evis Exera III Video System Center, Endoclot Phs, Endoclot Sis |
| Steris Corporation | $167.00 | 2023 | |
| Pentax of America, INC. | $118.00 | 2023 | Inspira |
| Pfizer INC. | $105.20 | 2025 | |
| Cook Medical LLC | $98.28 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumendi LLC | $51.61 | 2019 | |
| Ambu INC. | $46.69 | 2024-2025 | |
| Erbe USA INC | $34.41 | 2020 | |
| Alcresta Therapeutics, INC. | $33.20 | 2024 | Relizorb |
| Janssen Biotech, INC. | $25.65 | 2023 | Stelara, Remicade, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $22.38 | 2025 | Entyvio |
| Aimmune Therapeutics, INC. | $21.11 | 2025 | Zenpep |
| Celgene Corporation | $20.31 | 2023 | Zeposia |
| Regeneron Pharmaceuticals, INC. | $18.82 | 2022 | |
| Genzyme Corporation | $18.68 | 2023 | |
| Aries Pharmaceuticals, INC. | $13.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Davee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.